These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 18164542

  • 1. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P.
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O, Kieseier BC, Hartung HP.
    J Neurol Sci; 2007 Aug 15; 259(1-2):27-37. PubMed ID: 17391705
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 15; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec 15; 16(92):252-7. PubMed ID: 18092425
    [Abstract] [Full Text] [Related]

  • 10. [Advances in the treatment of multiple sclerosis?].
    Tackenberg B, Himmerich H, Wellek A, Oertel WH, Sommer N.
    MMW Fortschr Med; 2007 May 21; 149 Suppl 2():51-5. PubMed ID: 17724968
    [Abstract] [Full Text] [Related]

  • 11. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y.
    Rinsho Shinkeigaku; 2001 Dec 21; 41(12):1214-7. PubMed ID: 12235841
    [Abstract] [Full Text] [Related]

  • 12. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J.
    Mt Sinai J Med; 2011 Dec 21; 78(2):161-75. PubMed ID: 21425262
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G, Morrissey S, Le Page E.
    J Neurol Sci; 2004 Aug 15; 223(1):35-9. PubMed ID: 15261558
    [Abstract] [Full Text] [Related]

  • 15. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P.
    Nervenarzt; 2006 Dec 15; 77(12):1506-18. PubMed ID: 17136556
    [Abstract] [Full Text] [Related]

  • 16. Lessons from randomised direct comparative trials.
    Achiron A, Fredrikson S.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [Abstract] [Full Text] [Related]

  • 17. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B, Cepok S, Nessler S, Sommer N.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():23-8. PubMed ID: 11603112
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 19. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C, Tintoré M, Aguilera C.
    Med Clin (Barc); 2012 Sep 22; 139(7):316-8. PubMed ID: 22743277
    [No Abstract] [Full Text] [Related]

  • 20. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS.
    Phys Med Rehabil Clin N Am; 2005 May 22; 16(2):449-66, ix. PubMed ID: 15893681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.